Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation

Hwang, Shinn Jang; Luo, Jiing Chyuan; Chu, Chen Wei; Lai, Chiung Ru; Lu, Ching Liang; Tsay, Shyh Haw; Wu, Jaw Ching; Chang, Full Young; Lee, Shou Dong

doi:10.1046/j.1440-1746.2001.02407.x

Cited by 166 publications

(160 citation statements)

References 34 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…However, a study performed by Preumalswami et al, 2006 suggested that hepatic steatosis was not related to hepatic fibrosis in CHC infection. Hwang et al, 2001 have pointed out that the stage of hepatic fibrosis is generally advanced in patients with hepatic steatosis compared to those without steatosis.…”

Section: Resultsmentioning

confidence: 99%

Study of Hepatic Steatosis Index in Patients with Chronic HCV Infection

Elwan¹,

Elfert²,

Alska³

et al. 2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Study of Hepatic Steatosis Index in Patients with Chronic HCV Infection

Elwan¹,

Elfert²,

Alska³

et al. 2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…45 The influence of overweight has been emphasized recently; it is believed that steatosis related to overweight is responsible for the more rapid progression of fibrosis. [46][47][48] In addition, diabetes has been shown to be associated with fibrosis. 49 …”

Section: Factors Associated With Fibrosis Progressionmentioning

confidence: 99%

Fibrosis and disease progression in hepatitis C

2002

View full text Add to dashboard Cite

The progression of fibrosis in chronic hepatitis C determines the ultimate prognosis and thus the need and urgency of therapy. Fibrogenesis is a complex dynamic process, which is mediated by necroinflammation and activation of stellate cells. The liver biopsy remains the gold standard to assess fibrosis. Scoring systems allow a semiquantitative assessment and are useful for cross-sectional and cohort studies and in treatment trials. The rate at which fibrosis progresses varies markedly between patients. The major factors known to be associated with fibrosis progression are older age at infection, male gender, and excessive alcohol consumption. Viral load and genotype do not seem to influence significantly the progression rate. Progression of fibrosis is more rapid in immunocompromised patients. Hepatic steatosis, obesity, and diabetes may also contribute to more rapid progression of fibrosis. There are no tests that reliably predict the rate of progression of fibrosis in an individual patient. High serum alanine aminotransferase (ALT) levels are associated with a higher risk of fibrosis progression, and worsening of fibrosis is uncommon in patients with persistently normal serum aminotransferase levels. Serum markers for fibrosis are not reliable and need to be improved and validated. Liver biopsy provides the most accurate information on the stage of fibrosis and grade of necroinflammation, both of which have prognostic significance. Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis. (HEPATOLOGY 2002;36:S47-S56.)

show abstract

“…Factors like obesity, type 2 diabetes and hepatic steatosis predispose to both NASH as well as fibrotic progression in hepatitis C [30,31] . Obesity is recognised now as an independent risk factor for development of alcoholic cirrhosis [32].…”

Section: Discussionmentioning

confidence: 99%